Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ligelizumab retreatment and self-administration in chronic spontaneous urticaria
jRCT2080225155Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, double-blind, single-arm trial of ligelizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoints: Efficacy of ligelizumab retreatment and Safety and tolerability. Started Apr 2020; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080225155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225155.